HALO · Company research
Halozyme Therapeutics, Inc. (HALO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
41records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics | Zacks highlights five non-tech Nasdaq stocks with Zacks Rank #1 (Strong Buy) ratings positioned for Q4 gains. Ross Stores benefits from strong sales momentum and store expansion; Roku capitalizes on the shift from linear TV to streaming advertising; APA Corp offers favorable capital efficiency and long-term growth; Corcept Therapeutics sees strong demand for Korlym and new product launches; Halozyme benefits from collaboration royalties and milestone payments. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron | Zacks.com highlights five stocks showing strong relative price strength and outperforming the S&P 500: Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions Holdings, Permian Resources, and Chevron Corp. The article recommends focusing on stocks with consistent outperformance, solid fundamentals, and positive earnings estimate revisions in the current volatile market environment. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months - Stocktwits | These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| 5 Stocks to Buy Using the Relative Price Strength Strategy | U.S. equities remain resilient despite AI-linked tech weakness, with sector rotation indicating broader market strength. The article recommends a relative price strength strategy to identify stocks outperforming the S&P 500 with solid fundamentals and positive earnings revisions. Five stocks highlighted include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions Holdings, Permian Resources, and Chevron Corporation. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome | Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains | Despite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains | Despite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Yahoo Finance | Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance | Halozyme Therapeutics, Inc. (HALO) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| HALO Stock Climbs As Patent Win And Deals Lift Outlook - StocksToTrade | HALO Stock Climbs As Patent Win And Deals Lift Outlook StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| HALO Stock Climbs As Dutch Court Injunction Lifts Bullish Bets - Timothy Sykes | HALO Stock Climbs As Dutch Court Injunction Lifts Bullish Bets Timothy Sykes | View source ↗ | Timothy Sykes | Oct 14, 2026 | neutral | 0 | 0.6 |
| Top Research Reports for Mastercard, AstraZeneca & Sandisk | Zacks analysts published research on 16 major stocks on October 14, 2026. Mastercard received a Neutral rating despite strong performance, citing competitive pricing pressure and premium valuation concerns. AstraZeneca faces patent erosion challenges but benefits from strong pipeline drugs and expects $80 billion in revenues by 2030. SanDisk received an Outperform rating, driven by AI inference demand and strong datacenter exposure. Other notable stocks analyzed include Exelon, General Mills, and Halozyme, with mixed outlooks across various sectors. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.667 | 1 |
| HALO Stock Climbs As Patent Win Fuels Bullish Targets - StocksToTrade | HALO Stock Climbs As Patent Win Fuels Bullish Targets StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| HALO Stock Climbs As Patent Win And Targets Fuel Momentum - Timothy Sykes | HALO Stock Climbs As Patent Win And Targets Fuel Momentum Timothy Sykes | View source ↗ | Timothy Sykes | Oct 14, 2026 | neutral | 0 | 0.6 |
| HALO Stock Climbs As Patent Win And Targets Fuel Momentum - Timothy Sykes | HALO Stock Climbs As Patent Win And Targets Fuel Momentum Timothy Sykes | View source ↗ | Timothy Sykes | Oct 14, 2026 | neutral | 0 | 0.6 |
| HALO Stock Rallies As Patent Wins Boost Settlement Hopes - StocksToTrade | HALO Stock Rallies As Patent Wins Boost Settlement Hopes StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| Halozyme Therapeutics gains as partner-drug approval, patent win, and bullish analyst call lift sentiment - Quiver Quantitative | Halozyme Therapeutics gains as partner-drug approval, patent win, and bullish analyst call lift sentiment Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 14, 2026 | neutral | 0 | 0.6 |
| 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) | Halozyme Therapeutics is highlighted as an attractive growth stock pick with a Zacks Growth Score of A and Rank #1 (Strong Buy). The company demonstrates exceptional earnings growth of 112.1% projected for the year, significantly outpacing the industry average of 14.7%, along with strong asset utilization efficiency and positive earnings estimate revisions. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - Yahoo Finance | 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? | Halozyme Therapeutics has demonstrated a strong track record of beating earnings estimates, surpassing consensus by an average of 14.59% over the last two quarters. With a positive Earnings ESP of +2.78% and a Zacks Rank #2 (Buy) rating, analysts suggest the company is well-positioned to continue this earnings beat streak in its upcoming quarterly report. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance UK | Halozyme Therapeutics, Inc. (HALO) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| A director received 3,796 stock units at Halozyme (HALO), not the 6,796 originally reported. - Stock Titan | A director received 3,796 stock units at Halozyme (HALO), not the 6,796 originally reported. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| HALO Wins Court Order Blocking Merck's Keytruda SC in Europe | A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance | Halozyme Therapeutics, Inc. (HALO) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value? - Yahoo Finance | Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX | Halozyme Therapeutics announced an expansion of its collaboration with argenx, increasing exclusive ENHANZE technology targets from six to eight. The deal includes milestone payments and royalties on product sales. Halozyme raised its 2026 revenue guidance to $1.84-$1.91 billion, driven by strong royalty growth from J&J's Darzalex and argenx's Vyvgart Hytrulo. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX | Halozyme Therapeutics announced an expansion of its collaboration with argenx, increasing exclusive ENHANZE technology targets from six to eight. The deal includes milestone payments and royalties on product sales. Halozyme raised its 2026 revenue guidance to $1.84-$1.91 billion, driven by strong royalty growth from J&J's Darzalex and argenx's Vyvgart Hytrulo. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - TradingView | HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX TradingView | View source ↗ | TradingView | Oct 7, 2026 | neutral | 0 | 0.6 |
| A court halts Merck's under-the-skin Keytruda launch in several countries. Its vein-delivered version remains available. - Stock Titan | A court halts Merck's under-the-skin Keytruda launch in several countries. Its vein-delivered version remains available. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| A drug-delivery partnership expands from six exclusive targets to eight. - Stock Titan | A drug-delivery partnership expands from six exclusive targets to eight. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| A former director with more than 30 years in commercial leadership returns to Halozyme's board. - Stock Titan | A former director with more than 30 years in commercial leadership returns to Halozyme's board. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Our HALO Stock Swing Trade Featured An Angelic Exit - Investor's Business Daily | Our HALO Stock Swing Trade Featured An Angelic Exit Investor's Business Daily | View source ↗ | Investor's Business Daily | Aug 28, 2026 | neutral | 0 | 0.6 |
| Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair Value - Yahoo Finance | Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair Value Yahoo Finance | View source ↗ | Yahoo Finance | Aug 27, 2026 | neutral | 0 | 0.6 |
| HALO Stock Rises 36% in a Month: Here's What You Should Know - Yahoo Finance | HALO Stock Rises 36% in a Month: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Aug 21, 2026 | neutral | 0 | 0.6 |
| HALO Stocks in Emerging Markets Could Extend Rally as Heavy Industries Surge - Goldman Sachs | HALO Stocks in Emerging Markets Could Extend Rally as Heavy Industries Surge Goldman Sachs | View source ↗ | Goldman Sachs | Jun 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.